Accessibility Menu
Surface Oncology logo

Surface Oncology(NASDAQ) SURF

This security has been delisted. This page is retained for historical reference.

Surface Oncology last closing stock price
MetricPriceDate
Last closeUSD 1.072023-09-07
Surface Oncology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 1.072023-08-31
1 month+12.56%USD 0.952023-08-08
3 month+38.96%USD 0.772023-06-09
Year to date+30.49%USD 0.822022-12-30
1 year-18.94%USD 1.322022-09-07
3 year-82.34%USD 6.062020-09-04
5 year-89.56%USD 10.252018-09-07
Since inception-91.97%USD 13.332018-04-19

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

SURF Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-206.23%

Net Income Margin

-217.68%

Return on Equity

-61.52%

Return on Capital

-41.40%

Return on Assets

-40.84%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$30.00M

Operating Income

-$89.39M

EBITDA

-$92.72M

Operating Cash Flow

-$83.58M

Capital Expenditure

-$351.00K

Free Cash Flow

-$83.93M

Cash & ST Invst.

$56.26M

Total Debt

$9.49M

Surface Oncology Performance Analysis

Surface Oncology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 2,687,000N/A
20222022-12-31USD 30,000,0001016.5%
Surface Oncology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-30N/A
Q42022-12-31N/A
Q12023-03-31-100.0%
Q22023-06-30N/A
Surface Oncology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.77N/A
20222022-12-31USD -1.14-35.7%
Surface Oncology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-3014.9%
Q42022-12-3112.5%
Q12023-03-312.9%
Q22023-06-30-35.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

35

N/A

Net Income

-$28.19M

-9.3%

EBITDA

-$23.10M

+4.3%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$56.26M

-64.1%

Total Debt

$9.49M

-83.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$9.49M

+11.4%

Return on Assets

-40.84%

N/A

Return on Invested Capital

-43.07%

N/A

Free Cash Flow

-$19.54M

-535.9%

Operating Cash Flow

-$19.56M

-525.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QNCXQuince Therapeutics, Inc.
$18.51-1.44%
ACHLAchilles Therapeutics plc
$1.48+0.68%
RPHMReneo Pharmaceuticals, Inc.
$18.20+952.02%
TCRRTCR2 Therapeutics Inc.
$1.48+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.03+0.05%
PATHUiPath
$10.56-0.12%
NUNu Holdings
$14.43+0.00%
RIGTransocean
$5.28+0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.